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http://dx.doi.org/10.1016/j.ccell.2015.09.004SUMMARYT cell engineering is a powerful means to rapidly generate anti-tumor T cells. The costimulatory properties of
second-generation chimeric antigen receptors (CARs) determine the overall potency of adoptively trans-
ferred T cells. Using an in vivo ‘‘stress test’’ to challenge CD19-targeted T cells, we studied the functionality
and persistence imparted by seven different CAR structures providing CD28 and/or 4-1BB costimulation.
One configuration, which uses two signaling domains (CD28 and CD3z) and the 4-1BB ligand, provided
the highest therapeutic efficacy, showing balanced tumoricidal function and increased T cell persistence
accompanied by an elevated CD8/CD4 ratio and decreased exhaustion. Remarkably, induction of the
IRF7/IFNb pathway was required for optimal anti-tumor activity. Thus, 1928z-41BBL T cells possess strik-
ingly potent intrinsic and immunomodulatory qualities.INTRODUCTION
T cell engineering allows for rapid generation of T cells of any
desired specificity. The rationale for this approach to cancer
immunotherapy is to bypass the barriers to active immunization
to establish T cell-mediated tumor immunity (Brentjens et al.,
2003; Ho et al., 2003). Chimeric antigen receptors (CARs) are re-
combinant receptors for antigen, which, in a single molecule,
redirect T cell specificity and eventually enhance anti-tumor po-
tency. Functional augmentation is achieved through the design
of second generation CARs, which not only redirect cytotoxicity,
but also reprogram T cell function and longevity through their
costimulatory properties (Sadelain et al., 2009; van der Stegen
et al., 2015). Thus, human peripheral blood T cells that engage
antigen through a second-generation CAR receive both acti-
vating and costimulatory signals, resulting in cytotoxicity as
well as proliferation in the presence of tumor antigen, irrespec-Significance
CAR T cells are a promising immunotherapeutic approach for
CD28 or 4-1BB signaling domains have resulted in dramatic cl
lymphoblastic leukemia. We reveal here the different kinetics o
tages can be reconciled with adept receptor and ligand engin
display superior tumoricidal activity and robust persistence. Th
ports the anti-tumor activity of these T cells. Thus, CAR T cells
be useful to tackle a broad range of cancers, including solid tu
Ctive of the presence of costimulatory ligands (Maher et al.,
2002). T cells that stably express second generation CARs
thus acquire supra-physiological properties and become ‘‘living
drugs’’ that exert both immediate and long-term therapeutic ef-
fects (Sadelain et al., 2009).
Two decades ago, we selected CD19 as the prime target for
developing our CAR technology (Sadelain, 2015). Using immu-
nodeficient mice bearing a broad range of B cell malignancies,
including acute lymphoblastic leukemia (ALL), we showed a sin-
gle intravenous infusion of CD19 CAR targeted T cells could
eradicate tumor and induce long-term remissions (Brentjens
et al., 2003). CD19 has since become the poster child for CAR
therapies. Two types of second-generation CARs, using either
CD28 (Maher et al., 2002) or 4-1BB (Imai et al., 2004) as signaling
components have been used in patients and both have yielded
dramatic outcomes. Complete remissions have been obtained
in patients with various B cell malignancies, most consistentlyB cell malignancies. Second-generation CARs using either
inical responses, especially in patients with refractory acute
f these CARs and demonstrate that their respective advan-
eering. T cells receiving integrated CD28 and 4-1BB signals
ese T cells also activate the IRF7/IFNb pathway, which sup-
can be engineered to different levels of potency, which may
mors.
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Figure 1. Therapeutic Potency of First- and Second-Generation CAR Designs
One first-generation, 19z1, and two second-generation CD19-specific CARs, 1928z and 19BBz, were compared for their anti-tumor effect in a systemic NALM6
model.
(A) Flow cytometric analysis showing CAR and LNGFR expression.
(B) Cytotoxic activity using a 4 hr 51Cr release assay (left) and an 18 hr bioluminescence assay (right), using NALM6 as targets cells. Data are means ± SD.
(C) Cumulative cell counts of indicated CART cells uponweekly CD19 stimulation, without exogenous cytokines. Arrows indicate stimulation time points. Data are
means ± SD.
(D) NALM6 bearing mice were treated with 4 3 105 (top), 2 3 105 (middle), or 1 3 105 (bottom) indicated CAR T cells. Tumor burden shown as bioluminescent
signal quantified per animal every week over a 120-day period. Quantification is the average photon count of ventral and dorsal acquisitions per animal at all given
time points. Each line represents one mouse. Some groups are pooled from at least two experiments, representing n = 5–14 mice per group.
(E) Kaplan-Meier analysis of survival of mice in (D). *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S1.in ALL (Brentjens et al., 2011; Davila et al., 2014; Grupp et al.,
2013; Lee et al., 2015; Maude et al., 2014), reviewed in (Davila
et al., 2012; Ramos et al., 2014).
Here we model CD19 CAR therapy of ALL and evaluate CAR
designs that differ structurally in their recruitment of CD28
and 4-1BB signaling with the aim of unraveling the subtlety of
providing optimal costimulatory support to engineered T cells.
RESULTS
CD28 and 4-1BB Costimulation Induce Different Tumor
Elimination Kinetics
To compare the impact of the CD28 and 4-1BB costimulatory
domains of CARs on T cell anti-tumor functionality, we first as-
sessed the proliferative and cytolytic potential of 1928z and416 Cancer Cell 28, 415–428, October 12, 2015 ª2015 Elsevier Inc.19BBz T cells, using a first-generation CAR (19z1) as reference
(Figure S1A). To exclude potentially confounding effects im-
parted by different levels of CAR expression, we conducted all
studies using the same vector design (constant enhancer/pro-
moter and bicistronic vector structure) and strived to achieve
comparable CAR expression levels in all T cell groups within
each experiment (Figures 1A, S1B, and S1C). In vitro, the
19z1, 1928z and 19BBz T cell groups showed near-identical
cytolytic capacity (Figure 1B). However, in proliferation assays
(without addition of exogenous cytokines), both second-genera-
tion CARs showed greater T cell expansion and accumulation
upon weekly antigen stimulation, with the 19BBz CAR outper-
forming 1928z after 2 or 3 weeks (Figure 1C). To further compare
the therapeutic potential of peripheral blood T cells transduced
with these CARs, we devised a T cell ‘‘stress test’’ in which
Figure 2. In Vivo T Cell Accumulation and Tumor Burden Kinetics of First- and Second-Generation CAR Designs
NALM6-bearingmice were treated with 23 105 indicated CAR T cells. At 1, 2, and 3 weeks after CAR T cell infusion, mice were killed and bonemarrow cells were
harvested. CAR T cells and NALM6 cells were analyzed and counted with flow cytometry.
(A) Each dot represents one mouse, *p < 0.05; **p < 0.01.
(B) Each line represents n = 6 mice per group per time point. Red and green broken lines, respectively, indicate NALM6 cell number at the time of T cell infusion
and 1928z T cell accumulation at day 7.
(C) Effector/tumor (CAR T/NALM6) ratios were shown at different time points. All data are means ± SD. See also Figure S2.T cell doses are purposefully lowered to levels where CAR ther-
apy begins to fail, based on the previously described NALM6
pre-B ALL model (Brentjens et al., 2003; Brentjens et al., 2007).
Here, we lowered the treatment dose to 4 3 105, 2 3 105, and
1 3 105 CAR T cells (Figure 1D). Efficacy of tumor eradication
decreased with dose reduction within all groups, with both sec-
ond generation CARs consistently performing better than the
first generation construct (Figures 1D and 1E). The 1928z CAR
consistently showed more rapid tumor elimination and could still
induce a few complete remissions at a dose of 4 3 105 T cells,
but no longer at lower doses (Figures 1D and 1E). However, sur-
vival was still significantly extended at a dose of 2 3 105 CAR
T cells (Figure 1E). The 19BBz CAR also delayed tumor progres-
sion, albeit with noticeably slower kinetics than 1928z, as
increasingly obvious at lower T cell doses (2 3 105 and 1 3
105) (Figure 1D). To further analyze the kinetic differences in tu-
mor control between the different CARs, CAR T cells and tumor
cells were enumerated 7, 14, and 21 days post-infusion in the
bone marrow (Figures 2A and S2A) and spleen (Figure S2B) in
animals treated at the suboptimal T cell dose of 2 3 105 CAR
T cells. At day 7, CAR T cells accumulated to the same level
for both second generation constructs, but 1928z T cells had
already eliminatedmore tumor cells than 19BBz (Figure 2A), con-
firming themore rapid tumor elimination detected by biolumines-
cence (Figure 1D). By days 14 and 21, 19BBz T cells surpassed
1928z T cells in number and gradually caught up to 1928z T cellsCin terms of tumor cell elimination (Figure 2A). In contrast, the first-
generation 19z1 construct induced only modest T cell accumu-
lation, insufficient to achieve tumor control despite evident tumor
elimination at early time points (Figure 2A). Examination of T cell
and tumor cell numbers at multiple time points further reinforces
the differential kinetics of these different CARs (Figure 2B). Only
1928z T cells were able to induce a substantial tumor reduction
during the first 7 days. Because of limited expansion, 19z1 T cells
maintained a low effector:target (E:T) ratio and failed to achieve
tumor control (Figures 2B and 2C). Although 19BBz T cells accu-
mulated to higher levels than 1928z T cells by day 14, compara-
ble tumor cell elimination was still not achieved. (Figure 2B).
These measurements reveal that tumor eradication by 1928z
T cells is superior to 19BBz T cells, because tumor cell elimina-
tion is achievedwith a lower in vivo E:T ratio (Figure 2C). In aggre-
gate, these analyses confirm the enhanced expansion and func-
tion of second generation CARs but further reveal the greater
functional potential of 1928z T cells, which is compensated but
not exceeded over time by 19BBz T cells, owing to their greater
persistence.
Balancing Effector and Persistence Functions through
Optimally Combined Costimulation
Recognizing the distinct kinetic functions of the CD28 and
4-1BB-based CARs, we hypothesized that an optimal combina-
tion of these two costimulatory signals would result in bothancer Cell 28, 415–428, October 12, 2015 ª2015 Elsevier Inc. 417
Figure 3. Therapeutic Potency of a Third-Generation CAR and Three Alternative Combinations of Costimulatory CAR Designs
(A) Flow cytometric analysis showing expression levels of the indicated CARs.
(B) Cytotoxic activity using a 4 hr 51Cr release assay (left) and 18 hr bioluminescence assay (right), utilizing NALM6 cell line as targets cells. Data are means ± SD.
(C) Cumulative CAR T cell counts of indicated CAR T cells upon weekly CD19 stimulation, without exogenous cytokines. Arrows indicate stimulation time points.
Data are means ± SD.
(D) NALM6-bearingmice were treated with 23 105 (top), or 13 105 (bottom) indicated CAR T cells. Tumor burden showed as the bioluminescent signal quantified
per animal every week over a 120-day period. Quantification is the average photon count of ventral and dorsal acquisitions per animal at all given time points.
Each line represents one mouse. Some groups are pooled from at least two experiments, representing n = 7–14 mice per group.
(E) Kaplan-Meier analysis of survival of mice in (D). *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S3.accelerated and more profound tumor eradication if the proper-
ties of each CAR could be cumulated and reconciled. We there-
fore designed four configurations whereby the CD3z-mediated
activation and both CD28 and 4-1BB signals are solicited. The
1928BBz CAR is a third generation CAR design, as previously
described (Zhong et al., 2010). 19z1-CD80-41BBL uses two
costimulatory ligands, as previously described (Stephan et al.,
2007) (Figure S3A). The 1928z-41BBL and 19BBz-CD80 config-
urations combine each second-generation CAR with the ‘‘com-
plementary’’ costimulatory ligand (Figure S3A). As in the above
studies (Figures 1 and 2), comparable levels of CAR expression
were achieved, except for 1928BBz (Figure 3A). This CAR was418 Cancer Cell 28, 415–428, October 12, 2015 ª2015 Elsevier Inc.consistently expressed at a lower level (Figures S3B and S3C),
consistent with most other studies making use of triple-signaling
CARs (Carpenito et al., 2009; Tammana et al., 2010; Zhao et al.,
2009). All constructs had similar cytolytic capacity in vitro
(Figure 3B), which did not differ from their first- and second-
generation counterparts (Figure 1B). Expansion upon weekly
antigen stimulation without exogenous cytokines was enhanced
for all constructs compared to the second-generation CARs,
except for the 1928BBz construct, and strongest for the
1928z-41BBL configuration (Figure 3C). In vivo, however, the
constructs yielded very different outcomes. Among the three
superior combinations, 1928z-41BBL consistently emerged as
Figure 4. In Vivo T Cell Accumulation and Tumor Burden Kinetics of a Third Generation CAR and Novel Costimulatory Ligand and CAR
Combinatorial Designs
NALM6-bearingmice were treated with 23 105 indicated CAR T cells. At 1, 2, and 3 weeks after CAR T cell infusion, mice were killed and bonemarrow cells were
harvested from two femurs. CAR T cells and NALM6 cells were analyzed and counted with flow cytometry.
(A) Each dot represents one mouse, *p < 0.05; **p < 0.01.
(B) Each line represents n = 6 mice per group per time point. Red and green broken lines, respectively, indicate NALM6 cell number at the time of T cell infusion
and 1928z-41BBL T cell accumulation at days 7 and 21.
(C) Effector/tumor (CAR T/NALM6) ratios were shown at different time points.
(D) Cytotoxic activity of indicated ex vivo CAR T cells as shown using an 18 hr bioluminescence assay, using NALM6 cell line as targets cells. CAR T cells were
isolated from mouse spleens 3 weeks after treatment and pooled from 5–6 mice. All data are means ± SD.
See also Figure S4.themost potent, as reflected inmost effective tumor eradication,
highest frequency of long-term complete remission and highest
survival rates at the low dose of 13 105 CAR T cells (Figures 3D
and 3E). The enumeration of CAR T cells and tumor cells in the
bone marrow (Figures 4A and S4A) and spleen (Figure S4B)
showed that 1928z-41BBL T cells displayed the most elevated,
early T cell accumulation and most profound tumor cell eradica-
tion. Interestingly, despite poor T cell accumulation during the
first week, 1928BBz T cells induced significant early tumor con-
trol. However, these T cells failed to expand and induce com-
plete tumor eradication. Both 19BBz-CD80 and 19z1-CD80-
41BBLaccumulated to similar levels as 1928z-41BBLby 2weeks
after T cell injection; however, tumor cell elimination was less
than with the latter. The 19z1-CD80-41BBL T cells eventually
accumulated to high counts but were not able to prevent tumor
progression (Figures 4A and 4B). Measuring the T cell and tumor
cell counts within the different groups over time clearly showsCthat the strongest initial T cell expansion is achieved with
1928z-41BBL, resulting in rapid tumor cell clearance within the
first 7 days, more prolonged T cell persistence, eventually fol-
lowed by T cell contraction. The delayed expansion and weaker
effector function of 19BBz-CD80 and 19z1-CD80-41BBL allows
for tumor cell expansion resulting in lower E:T ratios at early time
points, which may eventually reach tumor eradication levels over
time (Figures 4B and 4C). We verified that cytotoxic functions
were maintained in vivo by performing ex vivo cytotoxicity as-
says using cells retrieved from the spleen 3 weeks after injection.
All three combinatorial designs showed effective cytolytic func-
tion (Figure 4D), similar to pre-infusion levels (Figure 3B), albeit
slightly higher for the 1928z-41BBL T cells (Figure 4D).
Impact on CD4 and CD8 T Cell Persistence
We further analyzed the phenotype of the persisting CD4 and
CD8 T cells, focusing on their relative ratio, phenotype, andancer Cell 28, 415–428, October 12, 2015 ª2015 Elsevier Inc. 419
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Figure 5. Optimally Combined 4-1BB and
CD28 Costimulation Promotes Higher CD8/
CD4 Ratios and Reduces T Cell Exhaustion
NALM6-bearing mice were treated with 2 3 105 of
indicated CAR T cells. Three weeks after CAR T cell
infusion, mice were killed and bone marrow cells
were harvested from two femurs. CD4 and CD8
CAR T cells were analyzed and counted with flow
cytometry.
(A) CD4 and CD8 CAR T cell percentage in each
mouse of indicated CAR design. Each black line
represents one mouse. The green line represents
the initial ratio at the time of infusion.
(B) FACS plots showing PD-1, LAG-3, and TIM-3
expression.
(C) Exhaustion marker analysis of (B).
See also Figure S5.expression of costimulatory receptors and exhaustion mar-
kers. The absolute cell counts of CD4 and CD8 T cell accumu-
lation at the tumor site (bone marrow) and in the spleen are
shown in Figures S2A, S2B, S4A, and S4B. Two major
patterns of CD8/CD4 ratio were observed. In most groups,
the ratio remained stable over 3 weeks, similar to the infusion420 Cancer Cell 28, 415–428, October 12, 2015 ª2015 Elsevier Inc.ratio (Figure 5A). Two of the groups,
corresponding to the two groups ex-
pressing 4-1BBL, diverged, showing an
inversion of the CD8/CD4 ratio: 1928z-
41BBL and 19z1-CD80-41BBL (Figures
S5A and 5A). The 19BBz group showed
an intermediate pattern, consisting in
a moderate rise in CD8/CD4 ratio
(Figure 5A).
Analysis of costimulatory receptor ex-
pression showed that all CAR T cell
groups gradually downregulated CD28
expression, more so in bone marrow but
also in spleen (Figures S5B and S5C). In
contrast, 4-1BB expression levels were
sustained, especially in bone marrow
(Figures S5B and S5C). The expression
of exhaustion markers/inhibitory recep-
tors PD-1, LAG-3, and TIM-3 was studied
in all groups showing T cell persistence
by week 3, namely 19BBz, 1928z-
41BBL, 19BBz-CD80, and 19z1-CD80-
41BBL (Figures 2 and 4). All three combi-
nations designed to engage both CD28
and 4-1BB pathways showed reduced
induction of PD-1, LAG-3, and TIM-3
relative to the second-generation 19BBz
CAR (Figures 5B and 5C). While their cu-
mulative expression was similar between
the three former groups, it should be
noted that 19BBz-CD80 T cells ex-
pressed the most PD-1, in bone marrow
as well as in spleen (Figures 5B, 5C,
S5D, and S5E). The analysis of other
T cell markers including KLRG1, CTLA4,and Fas showed less remarkable differences than the ex-
haustion markers (Figures S5F and S5G). No CCR7+CD62L+
CD45RA central memory T cells were detected 3 weeks
after T cell infusion. Most persisting CAR T cells had a
CCR7CD62LCD45RA effector memory phenotype (Figures
S5H and S5I).
Thus, the 1928z-41BBL configuration showed themost potent
tumoricidal profile, increased T cell persistence, supported the
highest CD8/CD4 ratio and induced the least PD-1 expression.
Combined CD28 and 4-1BB Costimulation Sustains
IRF7/IFNb Pathway Activation
To further understand the molecular mechanisms underlying the
improved anti-tumor function induced by 1928z-41BBL, we per-
formed genomewide gene expression profile of CD4 and CD8
1928z-41BBL T cells and compared it to 19z1-41BBL, 1928z,
and 19z1, which represent the elemental signaling modules
within the design. We found that 35% of the top-20 upregulated
genes in 1928z-41BBL, are type I interferon (IFN-I) targets. Anal-
ysis of curated pathway gene sets by gene set enrichment
analysis (GSEA) (Subramanian et al., 2005) confirmed a highly
statistically significant (p < 0.001; FDR < 0.001) enrichment of
IFN-I pathway in both CD4 (Figure 6A) and CD8 (Figure 6B)
1928z-41BBL T cells. To evaluate the contribution of each indi-
vidual signaling modality to the regulation of the IFN-I genes,
we compared their expression in all four groups. We found that
some of the IFN-I target genes were upregulated in 19z1-
41BBL T cells (Figures 6C and 6D), albeit to a lesser degree
than in 1928z-41BBL T cells. Thus, combined CD28 and 4-
1BB recruitment are required for potent induction of the IFN-I
pathway. We validated the elevation of IRF7, OAS1, and IFI6 in
both CD4 and CD8 1928z-41BBL T cells by real-time qPCR (Fig-
ure 6E). IRF7 is one of the main transcription factors regulating
the IFN-I pathway (Honda et al., 2005; Sato et al., 1998). IFNB1
transcripts markedly increased in 1928z-41BBL T cells 24 hr
after antigen stimulation, compared to that of 1928z T cells,
concomitantly with IRF7 but not IRF3 (Figure 6F). We did not
detect IFNA1 expression at any time point after antigen stimula-
tion (data not shown). Importantly, IRF7 and IFNB1 expression
were also induced in non-genetically modified human primary
T cells stimulated with CD3/CD28 beads and 4-1BBL compared
to CD3/CD28 bead stimulation alone (Figure S6), indicating that
combined CD28/4-1BB costimulation triggers IFN-I signaling in
human primary T cells independently of retroviral transduction
and CAR expression. IRF7 induction was confirmed in vivo in
adoptively transferred T cells. Thus, ex vivo induction of IRF7
and IFNB1 expression was detected in the three constructs ex-
pressing costimulatory ligands, as well as 19BBz. Importantly,
only 1928z-41BBL and 19BBz-CD80 sustained IRF7 expression
for at least 3 weeks in vivo (Figure 6G).
IRF7 Induction Augments the Anti-tumor Potential of
CAR T Cells
To assess the functional relevance of this induced IFN-I res-
ponse in human T cells, we knocked down IRF7 expression in
1928z-41BBL T cells, using two distinct shRNAs (IRF7sh1 or
IRF7sh2) and a control shRNA (shK) (Figure S7A). Effective
knockdown of IRF7 resulted in a marked reduction in both
IFNB1 and ISG15 induction (Figure 7A) as well as a reduction
of IFNb protein production (Figure 7B) in cultured T cells. To
determine whether IRF7 knockdown also had an effect on
cytolytic potential, we measured IFNg and granzyme-B produc-
tion 18 hr after antigen exposure. Both were reduced, and com-
parable to levels measured in 1928z T cells stimulated under
identical conditions (Figures 7C and S7B). Significantly, thisCdeficit could be restored through addition of exogenous IFNb
(Figure 7D). To determinewhether reduced IRF7 impacted in vivo
tumor rejection, we treated NALM6 bearing mice with 2x105 or
1x105 1928z-41BBL T cells expressing the control or anti-IRF7
shRNAs. Tumor burden monitoring revealed that 1928z-41BBL
T cells with reduced IRF7 expression were compromised, allow-
ing for continued tumor progression resulting in reduced overall
survival, in contrast to 1928z-41BBL T cells expressing the con-
trol shRNA (Figures 7E and 7F). Reduction of IRF7 expression did
not significantly reduce accumulation of T cells in the bone
marrow (Figure S7C) and blood (Figure S7D). In aggregate, these
findings demonstrate that the primary impact of IRF7 induction is
to augment the anti-tumor function of adoptively transferred
T cells, and that induction of IRF7, which is absent in 1928z
T cells, plays an important role in the augmented anti-tumor ac-
tivity of 1928z-41BBL T cells. Thus, the induction of the IRF7/
IFNb pathway, combined with the enhanced accumulation of
1928z-41BBL T cells, results in an improved balance between
T cell functionality, proliferation and persistence, resulting in su-
perior tumor eradication, which is evidenced at the lowest T cell
infusion doses.
DISCUSSION
The findings reported herein demonstrate the profound impact
of optimizing engineered costimulation on the function of adop-
tively transferred T cells. Natural costimulation is a dynamic pro-
cess that relies on a large number of costimulatory molecules,
which are spatially and temporally recruited to achieve different
functional outcomes (Chen and Flies, 2013; Miller and Sadelain,
2015). The genetic engineering of T cells is confined by technical
limitations on the number of transduced or targeted genes,
imposing a thoughtful analysis of which circuits to target and
how to do so. CD28 and 4-1BB costimulatory domains have
been the most widely used to date. The exact characteristics
of CD28 and 4-1BB-basedCARs have however not yet been fully
expounded (van der Stegen et al., 2015).
Under stringent experimental conditions, we studied their rela-
tive potency in a xenogeneic model of ALL. This test reveals ki-
netic differences that are undetected at high treatment doses.
Both CD28/CD3z and 4-1BB/CD3z-based CARs previously
showed convincing anti-tumor efficacy and achieved high com-
plete remission rates when used at high T cell doses, ranging be-
tween 5 and 20 3 106 CAR T cells (Brentjens et al., 2003, 2007;
Kowolik et al., 2006; Milone et al., 2009; Lee et al., 2011; Tsuka-
hara et al., 2013). We show here that clear differences in the ki-
netics of tumor control become apparent when lowering the
T cell doses to 1–23 105 CAR T cells. Thus, both second gener-
ation CARs outperform the first generation 19z1 CAR, but they
differ in their tumoricidal profile. 1928z T cells have greater
anti-tumor activity, as reflected in more rapid tumor clearance.
19BBz T cells mediate slower tumor elimination, but can achieve
similar tumor elimination owing to their greater persistence.
Recognizing these differential kinetics, we hypothesized that
an ideal combination of both signals would preserve the superior
tumoricidal capacity of CD28-based CARs with the sustenance
afforded by the 4-1BB-based CARs. The converse hypothesis
is that the two properties are antithetic and cannot be reconciled.
We explored four engineering solutions relying on differentancer Cell 28, 415–428, October 12, 2015 ª2015 Elsevier Inc. 421
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Figure 6. Antigen Activation Combined with CD28 and 4-1BB Costimulation Induces Strong Intrinsic Activation of the Type I IFN Pathway in
Human T Cells
Gene expression profiles were analyzed in stimulated CD4 or CD8 CAR T cells at day 15 in culture.
(A) GSEA analysis showing the enrichment of type I IFN signaling, in 1928z-41BBL versus 19z1 CD4 CAR cells.
(B) Same GSEA analysis in CD8 CAR T cells.
(C) Expression levels of type I IFN genes in indicated CD4 CAR T cells.
(D) Expression levels of type I IFN genes in indicated CD8 CAR T cells.
(E) Relative expression of IRF7 and two ISGs (OAS1 and IFI6), using qPCR for indicated CAR T cells. Data are means ± SD.
(legend continued on next page)
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structural conformations to engage T cell activation and costi-
mulation. The combined recruitment of CD28 and 4-1BB costi-
mulation proved to be highly sensitive to construct design. The
1928z-41BBL and 19BBz-CD80 configurations cumulate the
most favorable properties in terms of in vivo tumoricidal cyto-
toxicity, proliferation, persistence and IRF7 induction, although
they still significantly differ. Thus, 1928z-41BBL directs more
rapid tumor destruction than the 19BBz-CD80 configuration,
reminiscent of the 1928z versus 19BBz comparison, while the
added engagement of 4-1BB mediated by 4-1BBL extends the
persistence to 1928z T cells. Although the 1928z-41BBL and
19BBz-CD80 T cell populations are similar in their induction of
exhaustion markers and the induction of the IRF7/IFNb pathway,
they strikingly differ in the evolution of the CD8/CD4 ratio over
time. 1928z-41BBL directs the highest and most sustained
elevation of CD8 T cells. These combined features likely account
for the emergence of 1928z-41BBL as the winner in terms of
therapeutic efficacy in our ‘‘stress test,’’ resulting in complete re-
missions at doses of 13 105 and even 53 104 CAR T cells (data
not shown).
The 1928BBz and 19z1-CD80-41BBL configurations were the
least effective, albeit in different ways. 1928BBz directed robust
early tumor reduction but T cells failed to expand, while 19z1-
CD80-41BBL expanded steadily but exerted inferior tumor con-
trol. Under the specific conditions of the model, the time interval
to reach aCAR T cell to tumor ratio of 1:1, which is determined by
both T cell expansion (quantity) and effector function (quality),
serves as an indicator of T cell potency. The earlier this point is
reached, the higher the efficacy of the therapy. No such ratio is
ever attained with 19z1 CAR T cells. For 19z1-CD80-41BBL,
this point is reached relatively late, reflecting a poor balance
between effector and expansion functions. In the 5 remaining
designs (1928z, 19BBz, 1928BBz, 1928z-41BBL and 19BBz-
CD80), this point is reached by day 7, with 1928z-41BBL reach-
ing the highest E:T ratio (117.5), followed by 1928z (14.7).
The ‘‘stress test’’ model shows that the 1928z-41BBL con-
figuration captures all the features of rapid tumor elimination,
sustained proliferation and increased T cell persistence. Further-
more, exhaustion markers are reduced in 1928z-41BBL T cells
relative to 19BBz T cells. In aggregate, our findings suggest
that lower T cell doses of 1928z-41BBL T cells will be needed
in comparison to second generation CAR T cells, and that these
T cells will display longer persistence and a higher CD8/CD4 ratio
than obtained with either 1928z or 19BBz CAR therapy.
Providing costimulation in cis through the CAR or in trans
through ligand/receptor interaction will result in spatial and tem-
poral differences in the recruitment, kinetics and regulation of
costimulation. Thus, the constitutive expression of CD80 on
the T cell surface is not expected to be equivalent to the inclusion
of the CD28 signaling domain within the CAR due to CTLA4 inhi-
bition and receptor downregulation. Other structural constraints
bear on 4-1BB. The standard CAR design is a dimeric structure,
whereas the natural conformation of activated 4-1BB is trimeric(F) Relative expression of IFNB1, IRF7, and IRF3 at indicated time points after stim
lymphocytes (PBLs), highly purified CD4 or CD8 T cells. Data are means ± SD.
(G) Relative expression of IRF7 and IFNB1 at indicated time pointsmeasured by qP
was normalized to its first detectable expression level.
See also Figure S6.
C(van der Stegen et al., 2015), a structural difference that could
affect downstream signaling efficacy (Park et al., 1999). In
contrast, the use of 4-1BBL engages 4-1BB upon the latter’s in-
duction to the T cell surface, which is structurally and kinetically
distinct from the immediate 4-1BB clustering that occurs upon
19BBz binding to antigen.
At the molecular level, we conclude that 4-1BBL can effec-
tively complement 1928z CAR activity owing to the sustained
expression of 4-1BB over time, which contrasts with the gradu-
ally diminishing of CD28 expression, which averts the activity of
its constitutively expressed ligand. Thus, 4-1BBL ismore likely to
find its cognate receptor than CD80, while 1928z may compen-
sate for the loss of endogenous CD28, unlike 19BBz for endog-
enous 4-1BB. Additionally, the activity of CD80 may be further
constrained by CTLA-4, which is not the case for the CD28 signal
delivered through the 1928z CAR (Condomines et al., 2015).
These differences in the engagement of CD28 and 4-1BB
signaling pathways likely account for or contribute to the greater
efficacy of 1928z-41BBL relative to 19BBz-CD80.
In aggregate, the findings reported herein support our hypoth-
esis that optimized engagement of both CD28 and 4-1BB signals
can reconcile the tumoricidal capacity of CD28-based CARs
with the sustenance afforded by 4-1BB-based CARs, thereby re-
sulting in enhanced CAR T cell potency. Furthermore, our data
indicate that CD28 is the more powerful driver of an anti-tumor
response, which is best delivered through a CD28/CD3z CAR,
while the 4-1BB function is more productively coopted by
coexpressing 4-1BBL along with a CD28/CD3z CAR than by
the converse design (19BBz-CD80), the fusion of CD28 and 4-
1BB signaling domains (1928BBz), or the coexpression of both
cotimulatory ligands (19z1-CD80-41BBL). The very distinct out-
comes of these four CD28/4-1BB engineering conformations un-
derscore the enormous sensitivity and subtlety of integrating
costimulatory signals in activated T cells.
Our studies further reveal an IRF7-dependent activation of the
T cell IFN-I response pathway. Whereas IRF7 was transcribed
following 4-1BB costimulation in CD4 T cells (and to a lesser
extent in CD8 T cells), the persistence of its induction required
combined CD28/4-1BB engagement. The delicate balance of
optimal costimulation is again illustrated by the transient or de-
layed induction of IRF7 and IFNB1 in the less potent 19BBz
and 19z1-CD80-41BBL T cells.
In addition to requiring activation and costimulatory signals,
classically known as Signal 1 and Signal 2, respectively, the in-
duction of an effective T cell response also relies on cytokine
support, referred to as Signal 3. Signal 3 can support prolifera-
tion, clonal expansion, effector functions, and/or memory forma-
tion. A prominent example is type-I IFN, which supports CD8
T cell function (Curtsinger andMescher, 2010). Type-I IFN is pro-
duced by many cell types, including dendritic cells (DCs) (Ivash-
kiv and Donlin, 2014; Stetson and Medzhitov, 2006). In this
study, we found that human CAR T cells can produce significant
levels of IFNb, thereby supplying their own Signal 3. The ability ofulation, measured by qPCR in indicated CAR T cells generated from unselected
CR in purified ex vivo CAR T cell as described in Figures 2A and 4A. Each group
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Figure 7. IRF7 Is Required for Optimal Anti-tumor Efficacy of Human Targeted T Cells
(A) Graphs indicating expression of IRF7, ISG15, and IFNB1 before (unstimulated) and after antigen activation (stimulated) detected by qPCR in sorted human
T cells co-transduced with the 1928z CAR, 4-1BBL, a control shRNA (1928z+41BBL+shK+), or an anti-IRF7 shRNA (1928z+ 41BBL+ IRF7sh1+ and 1928z+ 41BBL+
IRF7sh2+). Human T cells expressing 1928z+LNGFR+shK+ were included for comparison. Data are means ± SD.
(B) Histograms showing IFNb protein levels, measured by ELISA in cell lysates of indicated T cell groups expanded in vitro for 7 days and restimulated or not with
irradiated NALM6 cells for 20 hr. Data shown are representative of five independent experiments. Data are means ± SD.
(C) IFNg and granzyme B (GRZB) were detected by intracellular FACS staining 18 hr after antigen stimulation in indicated T cell groups from six different donors.
Histograms show the average ± SEMof percentages of cells secreting the indicatedmolecules in CD4 or CD8 T cells. Values were normalized to that of 1928z+41-
BBL+shK+ T cells in each donor to minimize inter-individual variability.
(D) Impaired function induced by IRF7 knockdown is rescued by addition of IFNb. Intracellular cytokines were measured in the indicated T cell groups from four
different donors, stimulated as in (C) in the absence or presence of IFNb. Values were normalized to that of 1928z+41BBL+shK+ T cells in each donor to minimize
inter-individual variability. Data are means ± SEM.
(E) Plots representing the tumor burden weekly quantified by bioluminescence imaging per animal over a 50-day period. One line represents one mouse. n = 4–6
mice per group.
(F) Survival is illustrated in the Kaplan-Meier analysis. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S7.
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T cells to produce IFNb was previously reported in mouse CD8
T cells only (Ysebrant de Lendonck et al., 2013). We show here
that optimal augmentation of CD3z, CD28, and 4-1BB signaling
in 1928z-41BBL T cells results in a durable activation of IRF7/
IFNb signal pathway, especially in CD4 T cells. This correlates
with a stronger expansion of both CD4 and CD8 CAR T cells, re-
sulting in enhanced tumor regression immediately after T cell
injection.
The underlying mechanism(s) for mobilization of the IRF7/IFNb
pathway in T cells requires further examination. It is intriguing
that 4-1BB signaling involves TRAF2, which provides CD28-
independent costimulatory signals to resting T cells (Saoulli
et al., 1998) and that TRAF2 might be involved in IFN-I gene in-
duction (Sasai et al., 2010). There is also evidence that this
signaling can induce IFNb (Shin et al., 2006). Thus, the 4-1BB-
TRAF2-IFN-I pathway may operate in 1928z-41BBL T cells. In
this regard, although we did not see induction of mRNA for
IRF3, which encodes the transcription factor that triggers the
positive feedback loop of IFN-I induction by activating IFNB1
in virally infected cells (Honda and Taniguchi, 2006), it is known
that IRF3 is constitutively expressed; hence, it is not excluded
that IRF3 is activated by 4-1BB signaling, thereby initiating the
above described feedback loop. Obviously, further work will be
required to address these issues.
Another interesting issue is the underlying mechanism(s) by
which T cell-produced IFN-I exerts anti-tumor activities, which
we infer to be complex. First, IFNb produced at the site where
CAR T cells recognize the malignant cells would exert its anti-tu-
mor activities at locally high concentrations; it has been reported
that IFN-I is cytotoxic to ALL (Manabe et al., 1993). Second, the
activation of IRF7/IFNb in 1928z-41BBL T cells augments two
critical anti-tumor effector molecules, IFNg and granzyme B, in
both CD4 and CD8 T cells, wherein IFN-I in concert with T cell re-
ceptor stimulation robustly induces IFNg in CD8 T cells (Nguyen
et al., 2002). Indeed, IFNg is a key effector cytokine for T-cell-
dependent tumor immunotherapy (Ngiow et al., 2011; Nishikawa
et al., 2005; Wigginton et al., 2001). The potential anti-tumor
effects of IFNg are well documented, including direct anti-prolif-
erative and pro-apoptotic effects on tumor cells (Chin et al.,
1996; Ikeda et al., 2002), targeting of the tumor microenviron-
ment through inhibition of angiogenesis (Ikeda et al., 2002),
and stimulation of the innate and adaptive immune systems
(Jaime-Ramirez et al., 2011; Ngiow et al., 2011; Nishikawa
et al., 2005; Wigginton et al., 2001). Third, IFN-I may regulate
genes involved in CTL function by sustaining the expression of
T-bet and Eomes as well as through chromatin remodeling
(Agarwal et al., 2009; Lim et al., 2014), supporting the acquisition
of better effector function (Hervas-Stubbs et al., 2010; Marshall
et al., 2010; Mescher et al., 2006). Lastly, autocrine and para-
crine IFN-I may inhibit regulatory T cells in the tumor microenvi-
ronment, thereby breaking cancer immune tolerance as reported
in virally infected cells (Srivastava et al., 2014). We infer that
these and possibly othermechanismsmay be involved in an intri-
cate manner in the clinical outcome of 1928z-41BBL T cell ther-
apy. Thus, our current study sheds light on the classically known
anti-tumor activity of IFN-I in cancer immunotherapy.
In addition to the vigorous tumoricidal function imparted by
1928z, 1928z-41BBL T cells are poised to promote tumor erad-
ication throughmodulation of the tumormicroenvironment in twoCways. First, they facilitate targeted delivery of 4-1BB costimula-
tion via the display of a costimulatory ligand on the T cell surface,
resulting in trans-costimulation (Stephan et al., 2007). Second,
the local delivery of IFNb as ‘‘Signal 3’’ could enhance tumor
eradication inmultiple ways, by enhancing cross-priming activity
of DCs (Diamond et al., 2011; Fuertes et al., 2011; Yang et al.,
2014), inhibiting Treg activation and proliferation (Golding
et al., 2010; Srivastava et al., 2014), and disrupting the tumor
microvasculature (Spaapen et al., 2014). In a recent study, tar-
geted delivery of IFNb to the tumor site by an IFNb-antibody
fusion protein was shown to augment tumor antigen cross-pre-
sentation by CD8a DCs, activating CD8 T cells and inducing tu-
mor remission (Yang et al., 2014). Thus, CD28/CD3z CAR T cells
that co-express 4-1BBL are poised to recruit the host immune
response against the tumor, potentially diversifying the antigen
specificity of the immune response beyond the CAR target anti-
gen and stimulating immunity that outlives the CAR T cells them-
selves. The findings we report here thus offer perspectives for
T cell engineering in providing means to dial up or down effector
functions, modulate T cell persistence, and reprogram the tumor
microenvironment through a constellation of effects afforded by
the CAR T cell in trans. These properties are likely to be useful to
tackle a broad range of cancers, including solid tumors.
EXPERIMENTAL PROCEDURES
Retroviral Vector Constructs and Retroviral Production
Plasmids encoding the SFG g-retroviral vector (Rivie`re et al., 1995) were pre-
pared using standardmolecular biology techniques. LNGFR is a truncated and
mutated TNF-R family homolog (Gallardo et al., 1997) which was used as
a control molecule to ensure comparable CAR expression levels from different
bicistronic vectors. Synthesis of SFG-19z1-LNGFR, SFG-1928z, SFG-19BBz,
and SFG-VexGFP has been previously described (Brentjens et al., 2003, 2007;
Maher et al., 2002). The SFG-19z1-LNGFR plasmid that includes a P2A bicis-
tronic element was used as a template to obtain SFG-19z1-41BBL, 1928z-
LNGFR and SFG-1928z-41BBL constructs. SFG-1928BBz-hGFP was cloned
from SFG-P28BBz-hGFP as previous described (Zhong et al., 2010). VSV-G
pseudotyped retroviral supernatants derived from transduced gpg29 fibro-
blasts (H29) were used to construct stable retroviral-producing cell lines as
previously described (Gong et al., 1999).
Human T Cell Cultures and Retroviral Transduction
Blood sampleswere obtained from healthy volunteers under an institutional re-
view board-approved protocol, in accordance with the Declaration of Helsinki.
PBMC were isolated by low-density centrifugation on Lymphoprep (Accurate
Chemical and Scientific), activated with PHA for 48 hr and transduced on
two consecutive days by centrifugation on retronectin-coated (Takara), oncor-
etroviral vector-bound plates. Alternatively, CD4 and CD8 T cells were first
negatively purified by CD4 or CD8 T cell isolation kits (Miltenyi Biotec) and
then positively selected and activated by CD3/CD28 beads (Invitrogen). Seven
days after PHA or CD3/CD28-bead activation, transduced T cells were stained
for transduction rate measurements and either injected to tumor-bearing mice
or cocultured with irradiated confluent CD19+ NIH 3T3s, at 106 cells/ml in 24-
well tissue culture plates in RPMI medium supplemented with 10% FCS, with
no added cytokines. Identical stimulations in fresh medium were performed
weekly. Supernatants were harvested 24 hr after T cell stimulation for cytokine
detection. Total cells were counted and CAR expression was weekly deter-
mined by flow cytometry.
Microarray Procedure, Gene Expression Analysis, and Gene Set
Enrichment Analysis
Total RNA was extracted from three coculture replicates of CAR T cells, 20 hr
after the second in vitro stimulation on 3T3s, using TRIzolTM Reagent (Invi-
trogen Life Technologies). RNA quality control parameters and microarrayancer Cell 28, 415–428, October 12, 2015 ª2015 Elsevier Inc. 425
hybridization were performed at the MSKCC Genomics Core facility following
the standard Illumina protocol (Illumina). For gene expression analysis, we
applied quantile normalization to raw data using the Partek Genomincs Suite.
Differentially expressed genes among the four CAR T cells groups were deter-
mined by one-way repeated-measures ANOVA (p < 0.01) corrected by Benja-
mini-Hochberg’s false discovery rate method (p < 0.05). Heatmaps were
performed in Partek Genomincs Suite using normalized data standardized
on average. The complete data was deposited in the NCBI Gene Expression
Omnibus under accession number GEO: GSE68329. The GSEA (Subramanian
et al., 2005) was performed on curated pathway gene sets from the Broad
Molecular Signature Database (http://www.broadinstitute.org/gsea/msigdb/).
Mouse Systemic Tumor Model
We used 8- to 12-week-old NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice
(Jackson Laboratory), under a protocol approved by the MSKCC Institutional
Animal Care and Use Committee. Mice were inoculated with 0.53 106 FFLuc-
GFP NALM6 cells by tail vein injection followed by 1–4 3 105 CAR T cells four
days later. NALM6 produce very even tumor burdens and no mice were
excluded prior to treatment. No blinding method was used. Bioluminescence
imaging utilized the Xenogen IVIS Imaging System (Xenogen) with Living Image
software (Xenogen) for acquisition of imaging datasets. Tumor burden was as-
sessed as previously described (Gade et al., 2005).
T Cell and Tumor Cell Isolation from Bone Marrow and Spleen
For qPCR assay, CAR T cells were first negatively enriched by Dynabeads
mouse untouched T cells (Invitrogen) and human CD19 Beads (Miltenyi Biotec)
and subsequently positively purified using Dynabeads human CD3 (Invitro-
gen). For the cytotoxicity assay, CAR T cells were only negatively purified.
Statistical Analyses
Data were analyzed using Prism 5.0 (GraphPad Software). Statistical compar-
isons between two groups were determined by Student’s t tests. All p values
are two-tailed. The Log-rank test was used to compare survival curves ob-
tained with Kaplan-Meier method. For the in vivo studies, no pre-specified ef-
fect size was used to determine sample sizes. The use of statistical tests was
chosen according to the nature of the data. Comparison of survival curves was
done using the log-rank test. Statistical significance was defined as p < 0.05.
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